论文部分内容阅读
目的探讨多柔比星脂质体与吡柔比星所致静脉炎的发生率有无差异。方法观察147例应用外周浅静脉留置针输注化疗药物的非霍奇金淋巴瘤患者,分别应用吡柔比星(吡柔比星组)及多柔比星脂质体(多柔比星脂质体组)进行输注,观察并比较两组患者静脉炎发生率和局部疼痛的情况。结果多柔比星脂质体组静脉炎发生率为19.60%,吡柔比星组为76.04%;多柔比星脂质体组疼痛发生率为8.51%,吡柔比星组为100%,差异均具有统计学意义(P<0.01)。结论经外周应用多柔比星脂质体组静脉炎发生率及疼痛程度较应用吡柔比星组低。
Objective To investigate the difference of the incidence of phlebitis induced by doxorubicin liposomes and pirarubicin. Methods A total of 147 patients with non-Hodgkin’s lymphoma who received chemotherapy with peripheral venous indwelling needles were enrolled in this study. The effects of pirarubicin (pirarubicin group) and doxorubicin liposomes (doxorubicin Plastid group) were infused to observe and compare the incidence of phlebitis and local pain in both groups. Results The incidence of phlebitis in the doxorubicin liposome group was 19.60%, in the pirarubicin group was 76.04%, in the doxorubicin liposome group was 8.51%, in the pirarubicin group was 100% The differences were statistically significant (P <0.01). Conclusions The incidence and the degree of phlebitis in peripheral administration of doxorubicin liposomes are lower than those in the pirarubicin group.